Overview

Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

Study Design: Treatment, Randomized, Open Label, Parallel Assignment,Safety/Efficacy Study. The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) expanded ex-vivo infusion for the treatment of patients who have developed a newly diagnosed extensive or refractory chronic graft versus host disease (chronic GVHD) to the usual therapeutic measures.

Phase:

Phase 2

Details

Lead Sponsor:

Guangdong General Hospital
Guangdong Provincial People's Hospital

Collaborator:

Sun Yat-sen University

Treatments:

Cyclosporine
Cyclosporins
Methotrexate
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Tacrolimus